Friday, January 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

IITRI’s New Zika Model Supports Countermeasure Development

by Global Biodefense Staff
May 10, 2016
Zika Virus Diagnostics and Countermeasure Development

Zika Virus Diagnostics and Countermeasure DevelopmentIIT Research Institute (IITRI) scientists have developed a novel mouse model for Zika infections using the current viral strain responsible for outbreaks in Central and South America, and more than 1000 locally-acquired and imported cases in the U.S. and territories.

The Zika mouse model is urgently needed to rapidly test new drugs and vaccines against the same strain associated with microcephaly in newborns.

IITRI is one of the first labs in the country to have acquired the PRV ABC59 strain, an isolate of Zika virus from the current outbreak.

Robert Baker, PhD, Manager of the Microbiology and Molecular Biology Division at IITRI, emphasized the importance of using the current strain to evaluate new treatments against the Zika virus. “Most labs are working with old isolates—as old as 1947 in fact.  As you know, viruses and other organisms change over time, and those older isolates have never been associated with microcephaly. We are at the cutting edge of the effort to get an effective treatment or prevention out to the world.”

“We’re very excited to be able to offer a more relevant Zika mouse infection model to study the viral disease pathogenesis and find new treatments against the current Zika threat,” said David McCormick, PhD, DABT, Director of IITRI. “We have been working hard to have the model available for research to catch up with the emerging outbreak.”

IITRI has a long history of providing preclinical efficacy, safety, and toxicology services to the pharmaceutical, biotechnology, biodefense, consumer products and chemical industries as well as the U.S. Government. IITRI offers a wide range of services to support preclinical drug development of small molecules, vaccines, and biologics.

Tags: Animal ModelsEmerging ThreatsZika

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC